Madrigal Pharmaceuticals, Inc. SEC filings MDGL
Madrigal Pharmaceuticals, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Nov 12, 2010. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| UPLOAD | Letter from the SEC | Jan 25, 2024 | — |
| CORRESP | Letter to the SEC | Jan 17, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2024 | — |
| CORRESP | Letter to the SEC | Dec 14, 2023 | — |
| CORRESP | Letter to the SEC | Dec 8, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2023 | — |
| CT ORDER | Filing | Mar 12, 2019 | — |
| EFFECT | Filing | Jul 25, 2017 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2017 | — |
| CORRESP | Letter to the SEC | Jul 21, 2017 | — |
| D | Filing | Jul 5, 2017 | — |
| CT ORDER | Filing | Mar 15, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2016 | — |
| CORRESP | Letter to the SEC | Jun 1, 2016 | — |
| EFFECT | Filing | Oct 16, 2015 | — |
| CORRESP | Letter to the SEC | Oct 14, 2015 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2015 | — |
| EFFECT | Filing | May 14, 2014 | — |
| EFFECT | Filing | May 1, 2013 | — |
| CORRESP | Letter to the SEC | Apr 29, 2013 | — |
| UPLOAD | Letter from the SEC | Mar 19, 2013 | — |
| CT ORDER | Filing | Feb 24, 2012 | — |
| EFFECT | Filing | Aug 19, 2011 | — |
| CT ORDER | Filing | Aug 12, 2011 | — |
| CT ORDER | Filing | Aug 9, 2011 | — |
Showing 25 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MDGL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- West Conshohocken, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1157601
- Former names
- MADRIGAL PHARMACEUTICALS, INC. (until Nov 3, 2026); SYNTA PHARMACEUTICALS CORP (until Aug 1, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.